Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB HYDROCHLORIDE DIHYDRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB HYDROCHLORIDE DIHYDRATE.
CAPRELSA vs NILOTINIB HYDROCHLORIDE DIHYDRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Nilotinib is a BCR-ABL tyrosine kinase inhibitor that binds to and stabilizes the inactive conformation of the ABL kinase domain, thereby inhibiting proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
300 mg orally once daily, with or without food.
400 mg orally twice daily, approximately 12 hours apart, without food (at least 2 hours before or 1 hour after a meal).
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Approximately 17 hours (terminal elimination half-life; supports once-daily or twice-daily dosing; extensive accumulation with daily dosing, steady state by day 8)
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Fecal (93%), renal (3%; unchanged nilotinib appears minimal, mostly metabolites)
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor